NEWS
SUBSCRIBER SEARCH (Requires Login)
  NEW DRUGS
  MARKETED DRUGS
  COMPANY
  TARGETS IN ONCOLOGY
  NEWS SUMMARIES
  COMBINATION TRIALS

Latest Updates

January 2010 New Drug Updates and Additions

Designation

Brand Name

Generic Name

ACE-041

 

ACTB1003

 

 

ACTB1010

 

 

ACTB1011

 

 

ADXS11-001, Lm-LLO-E7

Lovaxin C

 

ANX-530, formerly SDP-012

 

Vinorelbine tartrate

ANX-514, formerly SDP-014

 

 

D-63153, SPI-153

 

Ozarelix

 

 

Talactoferrin alfa, talactoferrin

ALXN6000

 

 

E75

NeuVax

 

EG009, ad.HSV tk

Cerepro

 

AZD6244, ARRY-142886, ARRY-886

 

 

ATI-1123-Docetaxel

 

 

L19-IL2

 

 

BCX-1777

Fodosine

Forodesine hydrochloride

BI-505

 

 

Mycobacterial Cell Wall-DNA Complex (MCC), MCC/HA

Urocidin

 

BNP1350

 

Karenitecin

 

BiovaxID

 

 

Multikine

Leukocyte interleukin injection

CR011, CR011-vcMMAE

 

Glembatumumab vedotin

CP-4126

 

Gemcitabine 5'-elaidic acid ester

DOXO-EMCH, INNO-206

 

 

CUDC-305, CUDC-0305, Debio 0932.

 

 

ENMD-981693, ENMD-2076

 

 

PEG-SN38, EZN-2208

 

 

 

Graspa

 

Cur-691, GDC-0449, RG3616

HhAntag

 

G-202

 

 

XL880, XL-880, GSK1363089, GSK089

 

Foretinib

GSK2118436

 

 

GA101, RO5072759, RG7159

GlycoMAb

 

IMC-1121b, IMC 1121B (previously IMC-1CIIb, IMC-2C6, c-P1C11, IMC-1C11, DC101)

 

Ramucirumab

IMC-11F8

 

Necitumumab

IMC-3G3

 

 

IMC-EB10

 

 

IMMU-103, hLL2, hCD22, AMG 412

LymphoCide

Epratuzumab

IMMU-106, hA20, hCD20

 

Veltuzumab

IPI-926

 

 

INK128

 

 

IRX-2

 

Citoplurikin

KB004

 

 

MB7133, MB07133

 

 

LOR-253, ML-220, ML-series (ML-133 and LT-253)

 

 

G207

 

 

MK2206, MK-2206

 

 

HYB2055, IMO-2055, EMD 1201081

IMOxine

 

DI-B4

 

 

MGN1601

 

 

LEP-ETU (formerly PNU-93914)

 

Paclitaxel

Liposome Entrapped Docetaxel for Injection (LE-DT)

 

Docetaxel

NS-187, INNO-406, CNS-9

 

Bafetinib

DMXAA, AS1404, AS-1404, ASA404

 

Vadimezan

AVR118, AVR 118, OHR118

Formerly Product R or Reticulose

 

SC-1

 

 

PAT-LM1, LM-1

 

 

PAT-SM6, SAM-6

 

 

PAT-CM1, CM-1, NM1, PM1

 

 

CP-751871, CP-751,871

 

Figitumumab

RX-3117

 

 

PLX4032, PLX4720, RG7204, RO5185426

 

 

HuM195, SMART M195, SGN-33

Zamyl

Lintuzumab

SNS-595, SPC-595 (formerly AG-7352)

 

Voreloxin

TAP1, AdhTAP, AdhTAP(OS-1)

 

 

TL32711

 

 

TLN-4601, ECO-04601, ECO-4601, MW 462

 

 

TH-302, HAP-302

 

 

VNP40101M, 101M

Onrigin (formerly Cloretazine)

Laromustine

VM206

 

 

ZIO-201, ZIO-201-T

Zymafos

Palifosfamide, isophosphoramide mustard

  

Home   |    Freelance Opportunities   |   New Medicine   |   Site Map   |  Order/Inquiry   
SUBSCRIBER SEARCH:   NEW DRUG   |   MARKETED DRUG   |   COMPANY   |   TARGETS IN ONCOLOGY  

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887
INFO@NEWMEDINC.COM